Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30071381 | 0.86 | LMNA (0.42) | LMNAKCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL23214228 | 0.83 | LMNA (0.41) | LMNAKCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL27409551 | 0.81 | GAA (0.42) | LMNAKCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL22655935 | 0.78 | ALDH1A1 (0.46) | LMNAKCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL17054293 | 0.78 | EPHX2 (0.37) | KCNJ6KCNJ5KCNJ3ALDH1A1EPHX2 | |
| SCHEMBL31648588 | 0.77 | GRIN1 (0.45) | LMNAKCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL23950187 | 0.76 | POLB (0.46) | LMNA | |
| SCHEMBL113242 | 0.75 | LMNA (1.00) | LMNAALDH1A1KDM4EPKMGAA | |
| SCHEMBL27409525 | 0.75 | LMNA (0.49) | LMNAKCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL19301780 | 0.75 | CRHR1 (0.38) | LMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041729-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20220370451-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| EP-4041729-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021070054-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370451-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, SAMHD1, POLR2H | LMNA 3778/4885KCNJ6 4199/4885KCNJ5 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.